Signal 1 Facilitators and Signal 2 Facilitators, Their Immunomodulatory Compounds, Receptors They Act on and Principal Immune Responses They Elicit
9.5 VECTOR EXPRESSED VACCINES .1 dna V accIne
A major advantage of DNA vaccines over standard immunization approaches is that they may stim- ulate both cellular and humoral immune responses that protect fish against illness. This method of activating an immune response using genetically edited DNA is possible.73 Fish DNA vaccines have been studied and produced for a number of serious aquatic diseases since their initial publication in 1996. A circular plasmid dubbed a DNA vaccine contains an antigenic protein-producing gene from a disease of interest. In bacterial cells, the pathogen gene’s promoter and terminator regions as well as the DNA vaccine’s features enable it to be amplified to large numbers and utilized as a vac- cine. Despite the discovery of other promoters, the cytomegalovirus (CMV) promoter is still used in almost all DNA vaccines to generate high levels of constitutive expression. The plasmid invades a small number of host cells after DNA vaccine injection into a live host, causing the pathogen gene to be expressed and a little quantity of antigenic protein to be generated. So as to activate a wide range of protective immune responses, including both innate and adaptive immunity, the antigenic protein
Biotechnological Approaches to Vaccines 133
folds and processes as it would in the event of an actual pathogen infection.74 For various fish patho- gens, the extent to which DNA vaccines are developed is dependent on several variables, including (1) how important a pathogen is economically, (2) the lack of a successful vaccine produced by another strategy, (3) the pathogen’s ability to be cultured in the laboratory, (4) the pathogen’s protec- tive antigen(s), and (5) whether the pathogen is available.
Classic immunizations for bacterial fish illnesses, some of which may be administered by immer- sion, are quite effective. Thus, DNA vaccine research has focused on bacteria that are resistant to bacterins, which has led to the development of DNA vaccines. As a result, fewer DNA vaccines have been developed for more complicated illnesses like bacteria and cellular parasites since selecting effective antigens is more challenging. Infection with Renibacterium salmoninarum, which causes bacterial kidney disease (BKD) in salmonids, is an example of a bacterial-host association with complicated disease etiologies.75 Anti-Vibrio anguillarum DNA vaccines that encoded a crucial outer-membrane protein were found to be ineffective.76 Studies on A. veronii OMP48 found it to be a promising potential antigen, which led to the vaccines’ efficacy.77
DNA vaccines for infectious hemopoietic necrosis and viral hemorrhagic septicemia were approved by the FDA for use in 1996 and 1998, respectively.78,79 DNA vaccine plasmids have been shown to have a 65% survival rate in shrimp 15 days after inoculation, according to Rajeshkumar and coworkers.80 WSV envelope proteins were shown to be protective for 25–50 days in P. monodon after vaccination with DNA vaccines that included VP28 and/or VP281.81 For 7 or 14 days follow- ing immunization, L. vannamei were reported to be protected against WSSV infection by Li et al.82 who delivered an intramuscular VP28-encoding DNA vaccine to the animals. Survival against MrNV challenge was increased, viral load was reduced, and the immune system was strengthened to protect M. rosenbergii from MrNV infection by MrNV-CP-RNA-2-pVAX1.83 Current research on DNA vaccines for fish parasitic pathogens is ongoing. Most recent research has focused on iden- tifying prospective antigen genes that might be employed as DNA vaccines due to the increased level of complexity in these organisms. Protozoan ciliate Ichthyophthirius multifiliis (Ich) has been widely studied, and researchers have found antigens (i-antigens) that protect the host against the parasite.84 Protease genes from a hemoflagellate parasite, Cryptobiasalmositica, have recently been used in an effort to create an anti-virus for the salmon parasite, Cryptobiasoma.85 To their credit, rainbow trout that had been administered a DNA vaccination that expressed the metalloprotease virulence component recovered more quickly than control fish, even if the virus had not been com- pletely destroyed during the challenge. For the first time, the efficacy of a fish parasite DNA immu- nization was shown in this investigation.
9.5.2 rna VaccIne
Antigen-specific immune responses, especially cell-mediated responses, are generally stronger in RNA vaccines than in ordinary plasmid DNA vaccines. There is a new kind of vaccine that is less expensive, safer, and faster to produce than standard vaccinations: the mRNA vaccine.86 mRNA is a cellular protein-production blueprint generated from genetic information. Degradation occurs quickly when the protein is no longer required. DNA is unaffected by mRNA immuniza- tion because it does not enter the nucleus.87,88 There are two types of RNA vaccines, namely non- replicating mRNA and in vivo self-replicating mRNA. Dendritic cells that may transmit antigens to other immune cells in order to help activate an immune response are known as in vitro dendritic cell nonreplicating mRNA vaccines. A patient’s immune system is stimulated by the administration of RNA vaccine-infected cells that are subsequently administered back to the patient.89 When using RNA vaccines, they must be noninfectious and can be cleared by the body’s natural mechanisms.
RNA is a significant stimulant for the immune system, which is enhanced by RNA.86 Because of their increased effectiveness, constant immunological response, and stability, they are well toler- ated by healthy persons.89 Replicon vaccines based on the salmonid alphavirus 3 (SAV3) genome have been developed by Kalsen et al.90 that protect against infectious salmon anemia. It was shown
134 Fish Vaccines that ISAV hemagglutinin-esterase was particularly effective against Salmo salar, which is a virus.91 Viral infections in farmed fish may be prevented using mRNA vaccines, which have proved to be an effective and reliable method.92
9.5.3 recomBInant suBunIt VaccIne
Recombinant subunit vaccines are small, targeted proteins of a microbial pathogen that lack the capacity to multiply in the host, making them noninfectious. In addition, they could need sev- eral immunoadjuvant booster shots to guarantee long-lasting protective immunity.18 To more fully understand and generate the identified antigen, it is frequently essential to clone the gene encoding the protein. Heterologous protein expression has frequently been carried out in E. coli, but this method has some drawbacks in terms of the yield, folding, and posttranslational modifications of the recombinant protein.93 These issues can be resolved by using alternative expression systems like yeast, mammalian, and insect cell lines. For high-quality subunit vaccine production, the mam- malian and insect cell line expression systems offer a number of benefits, including proteolytic cleavage, glycosylation, secretion, folding, phosphorylation, acylation, and amidation.94 It is fea- sible to induce immunity against more than one strain or serotype of a bacterial or viral disease by including multiple proteins in a subunit vaccination.95 The pathogen and host are connected via OMPs. Thirumalaikumar et al.96 expressed recombinant subunit OMP and hemolysin proteins through pET-30b vector by the bacterial expression system and delivered to Labeo rohita. The treated fishes had higher survival and boosted the immune system. A. hydrophila S-layer recom- binant protein vaccinated carps had the highest protection and survival.97 V. harveyi recombinant OMP (VhhP2) subunit vaccine treated Japanese flounder had elicited strong immunoprotection.98 Viral hemorrhagic septicemia of trout (VHSV) protein fragments expressed in yeast S. cerevisia and treated to rainbow trout, Oncorhynchus mykiss, had higher immunological response.31 Wei and Xu99 used a baculovirus vector to express the WSSV rVP28 protein in silkworms (Bombyx mori) and examined the effectiveness of the vaccine in Procambarus clarkii. The results showed that the crayfish that had been given the rVP28 had considerably higher survival rates when exposed to the virus orally at 35 and 75 days after vaccination (dpv), respectively, of 54.16 and 59.26%. Caipang et al.100 expressed the WSSV VP28 in Brevibacillus brevis and delivered to Penaeus japonicus and challenged with WSSV. The shrimp fed the purified protein at the dose of 50 mg had 72.5%
survival. Penaeus chinensis treated with recombinant WSSV VP19 and VP466 subunit vaccines produced in Sf21 insect cells utilizing a baculovirus expression system fared better after WSSV challenge.101 Another recombinant WSSV envelope protein, rVP41A (VP292), was demonstrated to offer considerable protection for 30 days by Vaseeharan et al.102 Namikoshi et al.103 proved the quasi- immune response of P. japonicas against WSSV by delivering recombinant WSSV rVP26 and rVP28 with the immunostimulant β, 3-glucan, and Vibrio penaeicida, and the vaccinated groups had more than 95% survival. Two structural genes of WSSV VP19 and VP466 (VP28) of WSSV were cloned and expressed in Sf21 insect cells using baculovirus expression system and further its efficacy was studied by both intramuscular and oral routes and the vaccinated shrimp had more than 50% survival.101 According to Maftuch et al.,104 tiger shrimp were given two doses of the OMPs from V. alginolyticus, which had immunomodulatory effects and increased protection against V.
harveyi. Adult M. rosenbergii that had been injected with recombinant M. rosenbergii nodavirus capsid protein (r-MCP) responded well to the MrNV challenge.105 The baculovirus-expressed M.
rosenbergii nodavirus (MrNV) capsid protein produces protective immunity and increases survival against MrNV challenge in M.rosenbergii.106 VLPs, subunit vaccine components, are generated when viral capsid proteins self-assemble into particles that match the virus’ natural structure.107 Because VLPs lack genetic material, reversion mutations or pathogenic infection cannot occur, unlike with genuine viral particles.108 By recognizing and generating strong cellular and humoral responses to repeated subunits, VLPs, which cannot replicate in the receiver, may boost both the innate and adaptive immune responses of the recipient.109 To produce heterologous proteins, such
Biotechnological Approaches to Vaccines 135
as VLPs, baculovirus expression provides a cost-effective and efficient technique.110 E. lanceolatus showed a better resistance to infection after being exposed to varied concentrations of GNNV virus- like particles (VLPs).111 Researchers Chien112 and Cho113 have produced oral VLP vaccinations to protect grouper against NNV. The IPNV capsid protein VP2, produced in yeast, self-assembles into subviral particles (SVPs), and the injection of the SVPs into rainbow trout causes an immunological response, as reported by Dhar et al.114 In order to protect shrimp from the virus that causes white spot syndrome, Jariyapong et al.115 also created MrNV VLPs in E. coli and employed them as a vehicle to transmit double-stranded RNA (WSSV).
9.5.4 reVerse VaccIne
Methods based on bioinformatics predict the immunogenic sequences of pathogens to be used in vaccine production. An infectious organism’s whole antigenic repertoire may be exploited to find and test prospective vaccine candidates together with several defensive targets.116 Using this method, more vaccine candidates, including previously unknown and/or unusual proteins, may be discovered.
In addition, rational design’s capacity to make candidate antigens stronger might improve defenses against diseases using changeable antigens.117 Modern bioinformatics methods are used to predict suitable antigens for reverse vaccination. Extracellular and periplasmic areas, cell walls, cytoplasm, and outer-membrane parts of proteins should all be taken into account when making a judgment about using them as vaccine candidates. To examine transmembrane helices, adsorption potentials, and subcellular localization, we utilized PSORTb V3.0.2 server.118 The settings were manually mod- ified. PSI BLAST and the NCBI Conserved Domains Database (CDD) were used to identify putative domains for all of the most frequently encountered antigens.119 For the prediction of few antigens such as B-cell epitopes, BediPred linear epitope prediction tools from the Immune Epitope Database (IEDB) analysis resource are used. For a few antigens in the research, linear epitope prediction meth- ods such as BepiPred will be used to detect B-cell epitopes.120 We found that CTLPred’s artificial neural network and stabilized matrix approach implementation could effectively predict peptide’s ability to attach to MHC molecules in cytotoxic T-cells.121 VirusPloc is a useful tool for predicting the subcellular location of viral proteins in infected cells and in the host, as well as in cells infected by pharmacological targets.122 For membrane proteins, we can reliably predict the transmembrane helices using the TMHMM 2.0 server, a hidden Markov model-based approach. TMHMM 2.0 server.123 It is possible that the disulfide bond and molecular docking investigations may throw light on how modeling proteins and receptor molecules interact. The ClusPro v2.0 server is a widely used tool for protein-protein docking. In order to get the most accurate protein structure and its activities, Raptorx is the best server.124,125 Many bacterial, viral, and eukaryotic diseases are now being studied using this technology, and in every case, it has been successful in producing novel antigens for the creation of new vaccines.126 A promising method for finding recombinant vaccines for infectious, parasitic, and even metabolic illnesses is reverse vaccinology. There is a clear need to create stron- ger, safer, and better defined vaccines that can combine many antigens to create vaccinations that can protect against various pathogen strains. Recombinant vaccines satisfy this need, making them particularly appealing for use as animal vaccinations. Vaccine mixtures are a helpful immunization alternative for animals.127 The development of fish vaccines against a variety of important bacte- rial diseases, such as Photobacterium damselae subsp. piscicida, has increased the importance of reverse vaccination,128 Streptococcus agalactiae,129 E. tarda, and F. columnare.130 Several vaccines for fish RNA viruses, such as the Novirhabdoviruses IHNV and VHSV,131,132 the Alphavirus SDV,133 the Aquabirnavirus IPNV134 and also for several Betanodavirus species such as for the striped jack nervous necrosis virus (SJNNV) have been developed.135 Based on reverse vaccinology, Chukwu- Osazuwa et al.119 determined the common and distinctive antigens for Piscirickettsia salmonis, Aeromonas salmonicida, Yersinia ruckeri, Vibrio anguillarum, and Moritella viscosa. They came to the conclusion that 80 of these discovered antigens resembled exposed OMPs, while 74 of them matched secreted proteins (OMPs). Reverse vaccinology has been utilized to find novel antigens
136 Fish Vaccines for fish diseases including V. anguillarum and Photobacterium damselae subsp. piscicida.128,136 Using the primary capsid protein VP2 and RNA-dependent RNA polymerase (RdRp) genes as well as immunodominant T-cell epitopes and immunoinformatics, Islam et al.121 developed a vaccine against Lates calcarifer birnavirus (MABV). The vaccine was nonallergenic, had a high level of immunogenicity, and had good solubility. Based on conserved proteins in Streptococcus agalactiae, Kawasaki137 developed candidate serotype-independent preventive vaccines using a pan-genome reverse vaccinology technique (Group B Streptococcus; GBS). Vibrio parahaemolyticus multivalent vaccination was created by Wang et al.138 using a bioinformatics technique and the OMP protein for signaling peptides, transmembrane (TM)-helix, and subcellular location.
9.6 EXPRESSION METHODS FOR VACCINE DEVELOPMENT